Issue 36, 2005

Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients

Abstract

The carboxylic acid–primary amide supramolecular heterosynthon is exploited for the generation of pharmaceutical co-crystals that contain two active pharmaceutical ingredients that are polymorphic in their pure forms.

Graphical abstract: Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients

Supplementary files

Article information

Article type
Communication
Submitted
25 Jan 2005
Accepted
18 Jul 2005
First published
15 Aug 2005

Chem. Commun., 2005, 4601-4603

Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients

P. Vishweshwar, J. A. McMahon, M. L. Peterson, M. B. Hickey, T. R. Shattock and M. J. Zaworotko, Chem. Commun., 2005, 4601 DOI: 10.1039/B501304F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements